Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Randomized Study of Organ Care System Cardiac for Preservation of Donated Hearts for Eventual Transplantation (PROCEEDII)

This study has been completed.
University of California, Los Angeles
Columbia University
The Cleveland Clinic
Massachusetts General Hospital
Newark Beth Israel Medical Center
Cedars-Sinai Medical Center
Groupe Hospitalier Pitie-Salpetriere
Papworth Hospital
Azienda Ospedaliera S. Maria della Misericordia
Royal Brompton & Harefield NHS Foundation Trust
Indiana University
Information provided by (Responsible Party):
TransMedics Identifier:
First received: March 3, 2009
Last updated: May 11, 2015
Last verified: May 2015
The purpose of the study is to compare survival of both patients and newly transplanted hearts following heart transplantation among patients who were transplanted with donated hearts preserved on ice and those who were transplanted with donated hearts using the Organ Care System (OCS). The Organ care system preserves the hearts in a warm blood perfused beating state. The study also compares the number of rejection episodes, heart related adverse events, ICU time, and ventilation time between the two groups. The study is considered a success if survival in the OCS group was not inferior to the ice group.

Condition Intervention Phase
Heart Failure
Device: Organ Care System
Device: Cold Cardioplegia Solution
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Prospective, Multicenter, Randomized, Clinical Investigation of TransMedics Organ Care System (OCS) for Cardiac Use

Resource links provided by NLM:

Further study details as provided by TransMedics:

Primary Outcome Measures:
  • 30-day patient survival following transplantation with the originally transplanted heart and no mechanical circulatory assist device at day 30 [ Time Frame: 30 days ]

Secondary Outcome Measures:
  • Incidence of all cardiac graft-related serious adverse events [ Time Frame: 30 days ]
  • Incidence of biopsy proven ISHLT grade 2R or 3R acute rejection on any of the surveillance endomyocardial biopsies or clinically symptomatic rejection requiring augmentation of immunosuppressive therapy during the 30 day follow up [ Time Frame: 30 day ]
  • Length of ICU stay [ Time Frame: 30 day ]

Enrollment: 128
Study Start Date: March 2009
Study Completion Date: November 2013
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Organ Care System Device: Organ Care System
The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
Other Name: OCS
Active Comparator: Cold cardioplegia solution Device: Cold Cardioplegia Solution
This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Recipient Day of Transplant

  • Registered male or female primary heart transplant candidate
  • ≥18 years old
  • Signed, written informed consent document and authorization to use and disclose protected health information

Donor Hearts

  • <60 years old
  • Mean systolic blood pressure >60 mmHg at the time of final heart assessment
  • Satisfactory echocardiography assessment defined as:
  • Ejection fraction >40%
  • Absence of severe segmental wall motion abnormalities
  • Absence of left ventricular hypertrophy (inter ventricular septum and posterior wall thickness <1.3 cm)
  • Absence of valve abnormalities (trace to mild valvular regurgitation is acceptable)

Exclusion Criteria:

Recipient Day of Transplant

  • >4 previous sternotomies
  • Chronic renal failure as defined by chronic serum creatinine >3.0 mg/dL for more than 2 weeks and/or requiring hemodialysis (except for hemodialysis or hemofiltration for fluid overload)
  • Ventilator dependence at the time of transplant
  • Use of a ventricular assist device for > 30 days and the presence of any of the following: sepsis, intracranial hemorrhage or heparin induced thrombocytopenia
  • Panel reactive antibodies > 40% with a positive prospective cross match and/or virtual cross match
  • Use of an investigational drug or device, other than OCS, during the study.
  • Simultaneous transplant of non-heart allograft, except for concurrent kidney transplant

Donor Hearts

  • Abnormal coronary angiogram defined as >50% stenosis, requiring coronary bypass
  • Donor-to-recipient body weight ratio of <0.6
  • Inotrope support at time of final heart assessment including, but not limited to:

    • Dopamine >10 ug/kg/min
    • Dobutamine > 10 ug/kg/min
    • Milrinone >0.3 ug/kg/min
    • Epinephrine > 0.03 ug/kg/min
    • Norepinephrine > 0.03 ug/kg/min
    • Any bolus dose of the above prior to explants that would result in exceeding the above stated criteria
  • Presence of any exclusion criterion based on the standard practice of the investigational site
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00855712

United States, California
UCLA Medical Center
Los Angeles, California, United States, 90095
Cedars-Sinai Medical Center
Los Angeles, California, United States, 90211
United States, Indiana
Indiana University
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
United States, New Jersey
Newark Beth Israel Medical Center
Newark, New Jersey, United States, 07112
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
United States, Ohio
Cleveland Clinic
Cleveland, Ohio, United States, 44195
Hospitalier Pitie-Salpetriere
Paris, France, 75013
Azienda Ospedaliera S. Maria della Misericordia
Udine, Italy, 33100
United Kingdom
Papworth Hospital
Cambridge, United Kingdom, CB23 3RE
Harefield Hospital
London Borough of Hillingdon, United Kingdom
Sponsors and Collaborators
University of California, Los Angeles
Columbia University
The Cleveland Clinic
Massachusetts General Hospital
Newark Beth Israel Medical Center
Cedars-Sinai Medical Center
Groupe Hospitalier Pitie-Salpetriere
Papworth Hospital
Azienda Ospedaliera S. Maria della Misericordia
Royal Brompton & Harefield NHS Foundation Trust
Indiana University
Study Chair: Abbas Ardehali, MD University of California, Los Angeles
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: TransMedics Identifier: NCT00855712     History of Changes
Other Study ID Numbers: CAR-05-2008
Study First Received: March 3, 2009
Last Updated: May 11, 2015

Keywords provided by TransMedics:
Heart Failure
Warm Perfusion
Organ Care
Resting Mode

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Pharmaceutical Solutions
Cardioplegic Solutions processed this record on May 22, 2017